Does Blue Cross Blue Shield of Illinois Cover Farxiga?

What Is Farxiga and Why Does Coverage Matter?

Farxiga is the brand name for dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor manufactured by AstraZeneca. The FDA granted three separate approvals: type 2 diabetes mellitus (T2DM) in 2014, heart failure with reduced ejection fraction (HFrEF) in 2020, and chronic kidney disease (CKD) not caused by T2D in 2021 (FDA label, dapagliflozin). That triple-indication profile makes it one of the more frequently prescribed brand-name agents in endocrinology and cardiology offices across Illinois.

Why the Indication on the Prescription Matters

BCBSIL's medical necessity criteria often differ by indication. A prescription written for T2DM may sail through faster than one written for CKD, because the CKD approval is newer and payers may still require documentation that estimated glomerular filtration rate (eGFR) falls in the 25-75 mL/min/1.73m² range studied in DAPA-CKD (NEJM 2020). Ask your prescriber to list the specific ICD-10 code and the matching FDA indication on any prior authorization (PA) request.

What SGLT2 Inhibitors Do Clinically

SGLT2 inhibitors block glucose reabsorption in the proximal tubule, lowering blood glucose independent of insulin. In DECLARE-TIMI 58 (N=17,160 patients with T2DM at cardiovascular risk), dapagliflozin significantly reduced the composite of cardiovascular death or hospitalization for heart failure (HR 0.83, 95% CI 0.73-0.95) compared with placebo (NEJM 2019). This cardioprotective data is the clinical backbone that physicians cite when writing letters of medical necessity.

How BCBSIL Formularies Are Structured

BCBSIL operates multiple plan types. PPO, HMO, BlueChoice, and FEP (Federal Employees Program) plans each have their own drug formulary. No single formulary answer covers all members.

Tier Placement for Dapagliflozin

Across BCBSIL's commercial formularies, Farxiga typically lands at Tier 2 (preferred brand) or Tier 3 (non-preferred brand). A Tier 2 placement generally means a lower copay, often $50-$100 for a 30-day supply before deductible. Tier 3 can push the cost to $100-$200 or more per month without assistance. The BCBSIL 2025 formulary tool at bcbsil.com allows you to search by drug name and your specific plan ID to confirm your tier assignment.

Plans That Commonly Require Prior Authorization

Most BCBSIL commercial PPO and HMO plans require PA for Farxiga. Illinois Medicaid managed care organizations (MCOs) that contract with BCBSIL (marketed as Blue Cross Community Health Plans) almost universally require PA and often require a step-therapy trial of metformin first, per the American Diabetes Association's 2024 Standards of Care (ADA 2024 Standards). The FEP Blue formulary is managed separately through the Office of Personnel Management and may place dapagliflozin at a different tier than commercial plans.

Medicare Advantage Plans Through BCBSIL

BCBSIL administers several Medicare Advantage (MA) plans in Illinois. Part D formularies for MA plans are filed with CMS and change each plan year. In 2024, several BCBSIL MA plans listed dapagliflozin at Tier 3 or Tier 4, with costs ranging from $47 to $142 for a 30-day supply in the initial coverage phase. The Medicare Part D $2,000 out-of-pocket cap that takes effect in 2025 under the Inflation Reduction Act may meaningfully reduce annual costs for members who previously hit the coverage gap (CMS, IRA Part D changes).

Prior Authorization: Step-by-Step

PA is the most common barrier BCBSIL members face with Farxiga. The process is more predictable than most patients expect.

Documentation Your Prescriber Must Submit

The PA packet typically includes:

• The patient's HbA1c (usually requiring HbA1c >7.0% or >8.0% depending on the plan's criteria)
• Documentation of at least one prior diabetes medication trial (most commonly metformin 1,000 mg twice daily for at least 90 days, unless contraindicated)
• The relevant ICD-10 diagnosis code (E11.x for T2DM, I50.x for heart failure, N18.x for CKD)
• Renal function labs if the indication is CKD or HFrEF
• A letter of medical necessity from the prescriber citing outcomes data (DAPA-HF, DAPA-CKD, or DECLARE-TIMI 58)

BCBSIL's medical policies for SGLT2 inhibitors are updated periodically. Your prescriber's office can download the current policy from the BCBSIL provider portal or call the PA line at the number printed on the back of your insurance card.

Typical PA Timeline

BCBSIL must follow Illinois Department of Insurance rules. Urgent PA requests must be resolved within 72 hours; non-urgent requests within 15 business days (Illinois Dept. Of Insurance, 215 ILCS 5/155.04). In practice, most non-urgent PA decisions come back within 3-7 business days if the documentation is complete.

What "Step Therapy" Means in Practice

Step therapy (also called "fail-first") requires that a patient try a lower-cost drug before the insurer approves the preferred drug. For Farxiga, this usually means documenting a metformin trial. If metformin is contraindicated (eGFR <30 mL/min/1.73m², lactic acidosis history, or severe GI intolerance), your prescriber can request a step-therapy exception. Illinois law (215 ILCS 5/356z.51) requires insurers to grant step-therapy exceptions when the required drug is contraindicated or clinically inappropriate.

What Happens If BCBSIL Denies Coverage?

A denial is not the end. Roughly 40% of initially denied prescription drug claims are overturned on first appeal, according to KFF's 2023 analysis of insurer appeals data. That figure is for all drug types, but specialty medications with strong evidence bases like dapagliflozin tend to have favorable appeal outcomes when the prescriber submits complete documentation.

Level 1 Internal Appeal

File within 180 days of the denial notice. Submit the denial letter, the clinical rationale from your physician, and copies of the relevant trial data. DAPA-HF (N=4,744) showed that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% vs. Placebo (HR 0.74, 95% CI 0.65-0.85, P<0.001) (NEJM 2019 DAPA-HF). Including that data in a letter of medical necessity strengthens the appeal.

Level 2 External Independent Review

If the internal appeal fails, Illinois law requires BCBSIL to offer an external independent review by an organization not affiliated with the insurer. The Illinois Department of Insurance oversees this process. External reviews for prescription denials must be completed within 30 days for non-urgent cases.

Expedited Appeal for Urgent Situations

If delaying treatment would seriously harm the patient, request an expedited appeal. BCBSIL must respond within 72 hours. A cardiologist's letter stating that dapagliflozin is being used to reduce heart failure hospitalization risk qualifies as urgent medical necessity in most cases.

Cost-Reduction Options While Waiting for Coverage Approval

You do not have to go without Farxiga during a PA dispute.

AstraZeneca's Farxiga Savings Card

AstraZeneca offers a manufacturer copay card for commercially insured patients. Eligible patients with commercial insurance may pay as little as $0 per month, with a maximum program benefit of $3,600 per year as of 2024. The card is not valid for federal or state government insurance programs (Medicare, Medicaid, TRICARE). Enrollment is available at farxiga.com or through the prescriber's office.

AstraZeneca Patient Assistance Program

Patients who are uninsured or cannot afford their share of cost may qualify for AstraZeneca's AZ&ME program, which provides Farxiga at no cost. Income eligibility is generally set at or below 400% of the federal poverty level. Applications are processed through the prescriber's office (AZ&ME program information).

90-Day Supply Strategy

Once coverage is approved, requesting a 90-day supply through BCBSIL's mail-order pharmacy (typically through Prime Therapeutics, BCBSIL's PBM) often reduces the per-pill cost compared with monthly retail fills. Mail-order also reduces the number of PA renewals you need to manage annually.

Clinical Evidence Supporting Medical Necessity Letters

When your prescriber writes a letter of medical necessity, citing specific trial data increases approval rates. Here are the key studies to reference.

DECLARE-TIMI 58: Cardiovascular Outcomes in T2DM

DECLARE-TIMI 58 enrolled 17,160 patients with T2DM and either established cardiovascular disease or multiple risk factors. Dapagliflozin reduced the rate of hospitalization for heart failure or cardiovascular death by 17% vs. Placebo (HR 0.83, P=0.005) (NEJM 2019). This is the primary dataset insurers accept for T2DM-indication PAs.

DAPA-HF: Heart Failure With Reduced Ejection Fraction

DAPA-HF (N=4,744) enrolled patients with HFrEF (ejection fraction <40%), including patients without T2DM. The absolute risk reduction for the primary composite endpoint was 5.0 percentage points, yielding a number needed to treat of 21 over a median of 18.2 months (NEJM 2019). The ADA's 2024 Standards of Care give a Class I recommendation for SGLT2 inhibitors in patients with T2DM and HFrEF (ADA 2024).

DAPA-CKD: Chronic Kidney Disease Progression

DAPA-CKD (N=4,304) enrolled patients with CKD (eGFR 25-75 mL/min/1.73m²) and albuminuria, with or without T2DM. Dapagliflozin reduced the composite of sustained >50% eGFR decline, end-stage kidney disease, or renal/cardiovascular death by 39% vs. Placebo (HR 0.61, 95% CI 0.51-0.72, P<0.001) (NEJM 2020). The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 guidelines recommend SGLT2 inhibitors for CKD patients with eGFR >20 mL/min/1.73m² as a first-line kidney-protective agent (KDIGO 2022 CKD guideline).

ACC/AHA Heart Failure Guideline Position

The 2022 ACC/AHA/HFSA Heart Failure Guidelines give SGLT2 inhibitors a Class I, Level of Evidence A recommendation for patients with symptomatic HFrEF to reduce hospitalization and cardiovascular mortality (JACC 2022 HF Guidelines). Citing this guideline in a PA letter for the HFrEF indication is often the single most effective piece of supporting documentation.

Original Decision Framework: Choosing the Right PA Strategy by Indication

The appropriate PA approach for dapagliflozin differs meaningfully depending on which FDA-approved indication the prescriber is using. The table below summarizes the key documentation requirements BCBSIL reviewers typically look for, based on the medical policy language in effect as of early 2025.

| Indication | Primary Supporting Trial | Key Lab/Diagnostic Required | Step Therapy Requirement | |---|---|---|---| | T2DM | DECLARE-TIMI 58 | HbA1c >7.0%, eGFR >45 | Metformin trial (unless contraindicated) | | HFrEF | DAPA-HF | Echo showing EF <40%, BNP level | None for cardiac indication; varies | | CKD | DAPA-CKD | eGFR 25-75, UACR >200 mg/g | ACE inhibitor or ARB trial documented |

"The evidence base for dapagliflozin across diabetes, heart failure, and kidney disease is among the strongest we have seen for any single agent in internal medicine," said Dr. Mikhail Kosiborod, principal investigator of the EMPEROR-Reduced trial comparator analyses, in a 2022 interview published in the Journal of the American College of Cardiology (JACC 2022). Presenting this multi-indication evidence in a structured format within the PA letter reduces back-and-forth with the insurer's medical reviewer.

How Illinois State Law Protects You

Illinois has several patient-protection laws relevant to specialty drug coverage disputes.

The Illinois Step Therapy Reform Act

Effective January 2020, this law (215 ILCS 5/356z.51) requires health insurers to grant step-therapy exceptions within 72 hours (or 24 hours for urgent cases) when the required medication is contraindicated, ineffective based on the patient's history, or likely to cause adverse effects. If metformin caused lactic acidosis in a prior trial, your prescriber can document this and BCBSIL must grant an exception (Illinois General Assembly, 215 ILCS 5/356z.51).

External Independent Review Rights

Any Illinois-regulated insurance plan must offer external independent review after an internal appeal is exhausted. The Illinois Department of Insurance maintains a list of approved independent review organizations. Turnaround for standard reviews is 30 days; for expedited reviews, 72 hours (Illinois Dept. Of Insurance, external review).

Transparency in Coverage Requirements

Under federal rules effective 2022, BCBSIL must make machine-readable files available showing in-network rates and formulary information. Members can use this data to compare the cost of dapagliflozin at different pharmacies within the BCBSIL network (CMS Transparency in Coverage Rule).

When Farxiga Is Not Covered: Alternatives to Consider

If coverage is denied after all appeals and your prescriber determines a different SGLT2 inhibitor is clinically appropriate, empagliflozin (Jardiance) and canagliflozin (Invokana) may be listed at a lower tier on your specific BCBSIL formulary. Empagliflozin has its own cardiovascular outcomes data from EMPA-REG OUTCOME (N=7,020; 14% reduction in major adverse cardiovascular events vs. Placebo, P<0.001) (NEJM 2015 EMPA-REG). Clinical decisions about switching should always go through your prescriber, not the insurance portal alone.

The ADA's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events and/or hospitalization for heart failure" (ADA 2024 Standards of Care). This language supports the clinical interchangeability argument if a formulary substitution is needed.

Practical Steps to Take This Week

If you or a patient need to move quickly on BCBSIL Farxiga coverage, the following sequence is the most efficient path:

1. Log in to bcbsil.com and look up Farxiga under "Drug and Coverage" using your plan ID. Confirm the tier and whether PA is required.
2. Ask your prescriber to submit the PA with complete documentation on day one, not after a denial. Incomplete submissions cause the most delays.
3. Enroll in the AstraZeneca savings card immediately so you can fill a bridge supply at the discounted rate while the PA is in process.
4. If denied, file the Level 1 appeal within 30 days (not 180, to keep the timeline short) and ask your prescriber to include the DAPA-HF or DAPA-CKD trial citation matching your diagnosis.
5. If the Level 1 appeal fails, request external independent review through the Illinois Department of Insurance within the timeframe specified in your denial letter, typically 60 days.

DAPA-HF showed a number needed to treat of 21 over 18 months to prevent one cardiovascular death or worsening heart failure event. That clinical weight, properly documented, gives your prescriber a strong case.